Qualcomm Life's 2net Platform will serve as a global connectivity platform for collecting and aggregating medical device data during clinical trials
Qualcomm has announced that its subsidiary, Qualcomm Life, has been selected by Novartis, as a global digital health collaborator for its Trials of The Future program. Qualcomm Life's 2net Platform will serve as a global connectivity platform for collecting and aggregating medical device data during clinical trials to improve the convenience and speed of capturing study participant data and test results to ultimately gain more trial efficiencies and connected experiences for participants.
The Trials of The Future program is designed to leverage healthcare technology to improve the experience of clinical trial participants and patients using Novartis' products, and provide connectivity with future products marketed by Novartis. Novartis will combine the 2net Platform, 2net Hub and 2net Mobile technologies with designated medical devices to automate the collection of vital patient data at patient's homes during clinical trials.
"Novartis is a pioneer in putting technology to use in advancing pharmaceutical innovation. Standardizing on the tech-agnostic 2net Platform and accessing the robust ecosystem of integrated medical devices will provide them a great range of flexibility and scalability, ultimately accelerating their efforts to design more efficient, cost-effective clinical trials," said Mr Rick Valencia, senior vice president and general manager, Qualcomm Life.
Novartis is using the 2net Platform in a recently-launched clinical study, evaluating the use of mobile devices with chronic lung disease patients. The study, which is observational in nature and does not involve any Novartis pharmaceutical product, leverages 2net Mobile-enabled smartphones and 2net Hubs to seamlessly collect and aggregate biometric data from medical devices and transmits this data to the cloud-based 2net Platform, which securely sends the data to the study coordinator.